Hims & Hers Health has been assigned a Zacks Rank #5, or Strong Sell, as consensus earnings estimates for the company remain unchanged. The company is expected to post a loss of $0.06 per share for the current quarter, a year-over-year decline of 135.3%, while the full-year estimate stands at a loss of $0.23 per share, down 143.4% from the prior year. For the next fiscal year, the consensus estimate is $0.50 per share, representing a 320.9% increase, but this figure has also held steady over the past 30 days. Revenue projections show growth, with the current quarter estimate at $689.49 million, up 26.6% year-over-year, and full-year estimates of $2.9 billion and $3.4 billion for the current and next fiscal years, respectively. The stock has returned 26% over the past month, outperforming the broader market, but its valuation grade of F suggests it is trading at a premium to peers.
Hims Hers Health IncZacks assigns Strong Sell rating due to unchanged earnings estimates showing losses and decline.